Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its ...

The Alzheimer’s Association advised against diagnosing the disease on biomarkers alone, but other experts said the genie ...

A former Keolis engineer has pleaded guilty to wire fraud and tax evasion, admitting to stealing over $8 million from MBTA Commuter Rail funds, with sentencing in April.

Eli Lilly (NYSE ... below the guidance the company issued previously. And the key numbers investors were zeroing in on were sales of Mounjaro and Zepbound, which weren't great either.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...